CompanyCellTran was established in 2000 by Professors Sheila MacNeil and Robert Short at the University of Sheffield. These world-renowned researchers have, over a decade of research, brought together the disciplines of wound healing and advanced polymeric materials to create new spheres of activity in tissue regeneration and repair. It is from this collaboration that CellTran has begun to deliver the benefits of scientific advances.CellTran has developed advanced polymer surface technology and has optimised methods for the culture of autologous and allogeneic cells. We are able to clinically deliver these cells in prime condition for the active treatment of burns and chronic wounds. |
.jpg) CellTran’s facilities received accreditation by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2005, and CellTran was licenced as a registered tissue bank by the Human Tissue Authority (HTA) in August 2006.
|
| In October 2006 CellTran successfully merged with Xcellentis, acquiring a number of products to add to our active wound care portfolio, including Lyphoderm which will shortly enter Phase III clinical trials. CellTran has a management team with strong experience in emerging life-science technologies and is led by a CEO, with extensive experience in both the pharmaceutical and medical device sectors. All of CellTran's innovative technologies are protected by strong, worldwide IP positions. Our core patent was granted in March 2004 and we have a number of other patents upon which we welcome discussions with a view to granting licensing agreements. |
|